The DOI matches its Crossref record.
The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo
Abstract
Antimicrobial peptides have been shown to exert cytotoxic activity towards cancer cells through their ability to interact with negatively charged cell membranes. In this study the cytotoxic effect of the antimicrobial peptide, LfcinB was tested in a panel of human neuroblastoma cell lines. LfcinB displayed a selective cytotoxic activity against both MYCN‐amplified and non‐MYCN‐amplified cell lines. Non‐transformed fibroblasts were not substantially affected by LfcinB. Treatment of neuroblastoma cells with LfcinB induced rapid destabilization of the cytoplasmic membrane and formation of membrane blebs. Depolarization of the mitochondria membranes and irreversible changes in the mitochondria morphology was also evident. Immuno‐ and fluorescence‐labeled LfcinB revealed that the peptide co‐localized with mitochondria. Furthermore, treatment of neuroblastoma cells with LfcinB induced cleavage of caspase‐6, ‐7 and ‐9 followed by cell death. However, neither addition of the pan‐caspase inhibitor, zVAD‐fmk, or specific caspase inhibitors could reverse the cytotoxic effect induced by LfcinB. Treatment of established SH‐SY‐5Y neuroblastoma xenografts with repeated injections of LfcinB resulted in significant tumor growth inhibition. These results revealed a selective destabilizing effect of LfcinB on two important targets in the neuroblastoma cells, the cytoplasmic‐ and the mitochondria membrane. © 2006 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Studies on anticancer activities of antimicrobial peptides
Hoskin, D. W., & Ramamoorthy, A. (2008) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.11.008 · Cited by 1,296
From antimicrobial to anticancer peptides. A review
Gaspar, D., Veiga, A. S., & Castanho, M. A. R. B. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00294 · Cited by 749
Immunomodulatory and anticancer protein hydrolysates (peptides) from food proteins: A review
Chalamaiah, M., Yu, W., & Wu, J. (2018) · Food Chemistry · doi:10.1016/j.foodchem.2017.10.087 · Cited by 593
Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment
Mader, J. S., & Hoskin, D. W. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.8.933 · Cited by 430
Riedl, S., Zweytick, D., & Lohner, K. (2011) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2011.09.004 · Cited by 405
Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities
Tornesello, A. L., Borrelli, A., Buonaguro, L., Buonaguro, F. M., & Tornesello, M. L. (2020) · Molecules · doi:10.3390/molecules25122850 · Cited by 383
Lactoferrin, a bird’s eye view
Vogel, H. J. (2012) · Biochemistry and Cell Biology · doi:10.1139/o2012-016 · Cited by 260
Aguilar-Toalá, J. E., Santiago-López, L., Peres, C. M., Peres, C., Garcia, H. S., Vallejo-Cordoba, B., González-Córdova, A. F., & Hernández-Mendoza, A. (2017) · Journal of Dairy Science · doi:10.3168/jds.2016-11846 · Cited by 256
Roudi, R., Syn, N. L., & Roudbary, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01320 · Cited by 139
Discovery and development of a synthetic peptide derived from lactoferrin for clinical use
Brouwer, C. P. J. M., Rahman, M., & Welling, M. M. (2011) · Peptides · doi:10.1016/j.peptides.2011.07.017 · Cited by 90
Bridging machine learning and peptide design for cancer treatment: a comprehensive review
Rezaee, K., & Eslami, H. (2025) · Artificial Intelligence Review · doi:10.1007/s10462-025-11148-3 · Cited by 34
Metadata
- Authors
- Eliassen, L. T., Berge, G., Leknessund, A., Wikman, M., Lindin, I., Løkke, C., Ponthan, F., Johnsen, J. I., Sveinbjørnsson, B., Kogner, P., Flægstad, T., & Rekdal, Ø.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2006-05-08
- Volume
- 119
- Issue
- 3
- Pages
- 493-500
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2106801689
- Cited by
- 181
- References
- 0
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.